These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16965187)

  • 61. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Cognitive dysfunction and its therapy].
    Cesková E
    Cas Lek Cesk; 2005; 144(12):801-4. PubMed ID: 16389750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
    Carter CS
    Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Developing treatments for impaired cognition in schizophrenia.
    Minzenberg MJ; Carter CS
    Trends Cogn Sci; 2012 Jan; 16(1):35-42. PubMed ID: 22178120
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.
    Laughren T; Levin R
    Schizophr Bull; 2006 Apr; 32(2):220-2. PubMed ID: 16079389
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
    Nuechterlein KH; Robbins TW; Einat H
    Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical instruments to evaluate and guide treatment in schizophrenia.
    Marder SR
    Handb Exp Pharmacol; 2012; (213):1-10. PubMed ID: 23027410
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Wayne Fenton: impact on food and drug administration.
    Laughren T
    Schizophr Bull; 2007 Sep; 33(5):1153. PubMed ID: 17578891
    [No Abstract]   [Full Text] [Related]  

  • 70. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
    Carter CS; Barch DM
    Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Schizophrenia and cognition: long-standing and current issues].
    Azorin JM; Da Fonseca D; Fakra E
    Encephale; 2011 Dec; 37 Suppl 2():S93-4. PubMed ID: 22212848
    [No Abstract]   [Full Text] [Related]  

  • 72. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF
    Am J Psychiatry; 2007 Jul; 164(7):992-4. PubMed ID: 17606645
    [No Abstract]   [Full Text] [Related]  

  • 73. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
    Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
    Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Wayne Fenton and recovery.
    Bellack AS; Frese FJ
    Schizophr Bull; 2007 Sep; 33(5):1160-1. PubMed ID: 17567625
    [No Abstract]   [Full Text] [Related]  

  • 75. Methodological issues in negative symptom trials.
    Marder SR; Daniel DG; Alphs L; Awad AG; Keefe RS
    Schizophr Bull; 2011 Mar; 37(2):250-4. PubMed ID: 21270473
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Food and Drug Administration commentary on methodological issues in negative symptom trials.
    Laughren T; Levin R
    Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
    [No Abstract]   [Full Text] [Related]  

  • 77. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
    Kern RS; Green MF; Nuechterlein KH; Deng BH
    Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.
    Barch DM; Smith E
    Biol Psychiatry; 2008 Jul; 64(1):11-7. PubMed ID: 18400207
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
    Buchanan RW; Freedman R; Javitt DC; Abi-Dargham A; Lieberman JA
    Schizophr Bull; 2007 Sep; 33(5):1120-30. PubMed ID: 17641146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Standardized remission criteria in schizophrenia.
    van Os J; Burns T; Cavallaro R; Leucht S; Peuskens J; Helldin L; Bernardo M; Arango C; Fleischhacker W; Lachaux B; Kane JM
    Acta Psychiatr Scand; 2006 Feb; 113(2):91-5. PubMed ID: 16423159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.